2. Search Result
Search Result
Isoforms Recommended: MHC I
Results for "

MHC-I

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

5

Peptides

2

Inhibitory Antibodies

11

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1474
    WNT7A-IN-1 sodium

    		Wnt Cancer
    WNT7A-IN-1 sodium (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin . WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1 sodium
  • HY-P990193
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S)

    		MHC Inflammation/Immunology
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonal antibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S)
  • HY-158301
    MY-1B
    1 Publications Verification

    		 DNA Methyltransferase RNA MTase Others
    MY-1B is a covalent inhibitor of the RNA Methyltransferase NSUN2 (IC50: 1.3 μM). MY-1B stereoselectively ligands active-site cysteine residues (C271) of NSUN2. MY-1B can stereoselectively and covalently bind to PSME1, disrupting the proteasome regulatory complex and downregulating the presentation of specific MHC-I subtypes .
    MY-1B
  • HY-170411
    WNT7A-IN-1

    		Wnt Cancer
    WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1
  • HY-171859
    FC-14367

    		PROTACs HIV Cancer
    FC-14367 is a PROTAC degrader targeting HIV-1 Nef protein. FC-14367 forms a ternary complex by binding Nef and Cereblon E3 ubiquitin ligase, inducing Nef ubiquitination and proteasomal degradation, restoring cell-surface CD4 and MHC-I expression and inhibiting HIV-1 replication. FC-14367 can be used in research on HIV infection and AIDS . (Black: Glycolic acid (HY-W015967); Blue: 2-(2,6-Dioxopiperidin-3-yl)phthalimidine (HY-138793))
    FC-14367
  • HY-171860
    FC-14369

    		PROTACs HIV Cancer
    FC-14369 is a PROTAC degrader targeting HIV-1 Nef protein with a DC50 value of 160 nM. FC-14369 binds to both Nef and Cereblon E3 ubiquitin ligase via its bifunctional structure, inducing Nef ubiquitination and proteasomal degradation to restore cell-surface CD4 and MHC-I expression and inhibit HIV-1 replication. FC-14369 can be used in research on HIV infection and AIDS . (Pink: Nef ligand-2 (HY-171862); Black: Ethylenediamine (HY-Y0275); Blue: Thalidomide (HY-14658))
    FC-14369
  • HY-P10433
    EGFRvIII peptide

    		Apoptosis Cancer
    EGFRvIII peptide is an EGFRvIII-derived epitope for binding to MHC I molecules. EGFRvIII peptide induces apoptosis, and causes specific immune responses against glioblastoma, especially in combination with Flagellin B .
    EGFRvIII peptide
  • HY-P5745
    TYVPANASL

    		Transmembrane Glycoprotein Cancer
    TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .
    TYVPANASL
  • HY-P5745A
    TYVPANASL TFA

    		MHC EGFR Cancer
    TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .
    TYVPANASL TFA
  • HY-162965
    Immunoproteasome activator 1

    		Proteasome Cancer
    Immunoproteasome activator 1 (compound A) is a selective immunoproteasome activator that increases the presentation of individual MHC-I–bound peptides by over 100-fold. Immunoproteasome activator 1 binds to the proteasome structural subunit PSMA1 and promotes the association of the proteasome activator PA28α/β (PSME1/PSME2) with immunoproteasomes .
    Immunoproteasome activator 1
  • HY-P990061
    Polzastobart

    JTX 8064

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
    Polzastobart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: